We take aim at the world’s most intractable diseases. Our portfolio spans internal as well as partnered programs, across both novel and known (but traditionally undruggable) targets.
Indication
rModality
Target
Discovery
Pre-clinical
Clinical
Undisclosed
ALS
Proprietary
Cancer
Cancer
SM
SM
SM
SM
SM
ASO
Proprietary
FTD/AD
ALS
Proprietary
SM
SM
Proprietary
FTD/AD
FTD/AD
Undisclosed
Proprietary
Proprietary
ALS
SM = small molecule rModality = RNA-targeted modality
